Core Insights - The company continues to grow and invest in its products and platforms despite uncertain market conditions, focusing on expanding its presence in various verticals [2] - There is a strong emphasis on developing digital capabilities in Europe, supported by government initiatives and the European Union's push for digital sovereignty, which aligns with the company's investment strategy [2] - The company aims to be a preferred choice for European governments and enterprises, enhancing its digital foundation for a prosperous Europe [3] Financial Performance - In Q2 2025, the company reported a revenue growth of 3.9% to DKK 1,714.9 million, while adjusted EBITDA decreased by 18% to DKK 220.7 million, resulting in an adjusted EBITDA margin of 12.9% [5] - The diluted earnings per share for Q2 2025 were DKK 1.17, with an increase in the average number of full-time employees from 7,884 in Q2 2024 to 8,333 in Q2 2025 [5] - Free cash flow was DKK 25.6 million in Q2 2025, down from DKK 148.2 million in Q2 2024, with a cash conversion ratio of 14.6% [5] Future Guidance - The company maintains its financial guidance for the year, expecting organic revenue growth between 5% and 10% and an organic adjusted EBITDA margin between 16% and 19% [4][5] - Non-organic revenue through Netcompany Banking Services is projected to be between DKK 840 million and DKK 870 million for the full year [5]

Core Viewpoint - DEMIRE Deutsche Mittelstand Real Estate AG has reported lower earnings for the first half of 2025 compared to the previous year, primarily due to opportunistic property sales, but the performance exceeded its own guidance [2][3]. Financial Performance - Rental income decreased by 21.7% to EUR 27.8 million in H1 2025, down from EUR 35.5 million in H1 2024 due to property sales [3][8]. - Earnings before interest and taxes (EBIT) fell to EUR -24.9 million in H1 2025, compared to EUR -14.1 million in H1 2024, largely due to write-downs on loans to Limes companies amounting to EUR -12.5 million [3]. - Funds from operations (FFO I) after taxes and before minority interests and interests on shareholder loans amounted to EUR 5.0 million in H1 2025, down from EUR 15.5 million in H1 2024 [4][8]. Property Sales and Portfolio Performance - The market value of DEMIRE's portfolio declined to approximately EUR 747.3 million as of 30 June 2025, down from EUR 779.3 million at the end of 2024, influenced by property sales and value adjustments [5]. - The net asset value (NAV) per share decreased by EUR 0.48 to EUR 1.97 in the reporting period [5]. - Letting performance improved, with 40,460 square meters leased in H1 2025 compared to 25,000 square meters in H1 2024, although the EPRA vacancy rate rose to 17.3% [5]. Debt and Liquidity Management - The net debt ratio (net LTV) was reported at 42.4%, slightly above the previous year's figure of 40.9% [6]. - Cash and cash equivalents decreased to EUR 34.9 million as of 30 June 2025, down from EUR 44.8 million at the end of 2024 [6]. - The company has initiated partial repayment of its corporate bond, with the outstanding nominal now at EUR 247.1 million [6]. Future Guidance - The company has raised its guidance for 2025, expecting rental income to be between EUR 52.0 million and EUR 54.0 million, up from the previous range of EUR 51.0 million to EUR 53.0 million [7][8]. - FFO I is now expected to be between EUR 5.0 million and EUR 7.0 million, an increase from the prior forecast of EUR 3.5 million to EUR 5.5 million [9].

Group 1 - Sampo plc has initiated a share buyback program with a maximum value of EUR 200 million, starting on 7 August 2025 [1][2] - On 13 August 2025, Sampo plc acquired a total of 330,528 A shares at a daily weighted average price of EUR 9.76 [1] - Following the transactions, Sampo plc owns a total of 1,646,806 A shares, representing 0.06% of the total number of shares [2] Group 2 - The share buyback program is in compliance with the Market Abuse Regulation (EU) 596/2014 and the Commission Delegated Regulation (EU) 2016/1052 [1] - The authorization for the buyback program was granted by Sampo's Annual General Meeting on 23 April 2025 [1]

Core Viewpoint - Nilfisk's Q2 results indicate challenges and progress amid market caution and geopolitical uncertainties, with a slight decline in organic growth but stable gross margins and a focus on cost improvements and supply chain strengthening [1][4]. Financial Highlights - Revenue for Q2 2025 was 268.9 million EUR, down from 278.4 million EUR in Q2 2024, reflecting a decline of 9.5 million EUR [2][4]. - Organic growth was negative at -1.1% for Q2 2025, compared to a positive 2.4% in Q2 2024 [2][4]. - Gross margin remained stable at 42.0%, a slight decrease from 42.2% in the previous year [2][9]. - Overhead costs decreased to 92.2 million EUR from 94.2 million EUR year-on-year, with an overhead cost ratio of 34.3% [2]. - EBITDA before special items was 36.4 million EUR, down from 39.2 million EUR, resulting in an EBITDA margin of 13.5% [2][9]. - Free cash flow was negative at -16.3 million EUR, compared to a positive 8.4 million EUR in the same quarter last year [2][11]. Regional Performance - EMEA region showed organic growth of 0.7% in Q2 2025, driven by strong commercial execution and new products, although the Consumer Business faced declines [7]. - APAC reported moderate organic growth of 2.7%, while the Americas experienced negative growth of 4.9%, primarily due to soft demand and production capacity issues [8]. - Latin America continued to perform well with a strong growth rate of 14.0% [8]. Specialty and Consumer Business - The Specialty Business achieved robust organic growth of 10.8%, supported by strong sales in the US and demand for new products [5]. - The Consumer Business saw a decline of 5.1% due to weak demand in the high-pressure washer category [5]. Cost Management and Outlook - A cost reduction program was initiated in Q2 2025, leading to workforce reductions and expected gradual savings throughout 2025 and into 2026 [10]. - The financial outlook for 2025 remains unchanged, with organic growth expected between 1% and 3% and an EBITDA margin before special items projected between 13% and 14% [3].

Financial Reporting Schedule - Marimekko Corporation will publish its Financial Statements and the Report of the Board of Directors for 2025 in week 13, at the latest [1] - The Financial Statements Bulletin for 2025 is scheduled for Thursday, 12 February 2026, at 8:00 a.m. [4] - Interim Reports for 2026 will be published on the following dates: 13 May 2026 for Q1, 13 August 2026 for H1, and 4 November 2026 for Q3 [4] Annual General Meeting - The Annual General Meeting is planned for Thursday, 16 April 2026, at 2 p.m. [2] - Shareholders can request agenda items for the meeting by sending a written request to the Board of Directors by 15 January 2026 [2] - An announcement regarding the resolutions of the Annual General Meeting will be released after the meeting [2] Company Overview - Marimekko is a Finnish lifestyle design company known for its original prints and colors, with a product portfolio that includes clothing, bags, accessories, and home décor items [3] - In 2024, Marimekko reported net sales of EUR 183 million and a comparable operating profit margin of 17.5 percent [3] - The company operates approximately 170 stores globally and serves customers in 39 countries through its online store, with key markets in Northern Europe, the Asia-Pacific region, and North America [3]

Company Overview - Basilea Pharmaceutica Ltd is a commercial-stage biopharmaceutical company focused on addressing severe bacterial and fungal infections, headquartered in Allschwil, Switzerland [11] - The company has successfully launched two hospital brands: Cresemba for invasive fungal infections and Zevtera for bacterial infections [11] Licensing Agreement - Basilea has entered into an exclusive license agreement with Venatorx Pharmaceuticals to acquire global rights to ceftibuten-ledaborbactam etzadroxil, a clinical phase 3-ready oral beta-lactam/beta-lactamase inhibitor combination for complicated urinary tract infections (cUTI) [1][3] - The agreement includes an upfront payment and potential milestone payments in 2025, with total potential milestone payments of up to USD 325 million [3] Product Details - Ceftibuten-ledaborbactam etzadroxil combines ceftibuten, an orally bioavailable cephalosporin antibiotic, with ledaborbactam etzadroxil, a prodrug of a novel beta-lactamase inhibitor [2][6] - This combination shows bactericidal activity against multidrug-resistant pathogens, which are a major cause of cUTI, with over 600,000 hospital admissions annually in the USA [2] Clinical Development - Basilea plans to start a registrational phase 3 program for cUTI in approximately 18 months [3] - The product has received Qualified Infectious Disease Product (QIDP) and Fast Track designations from the US FDA for cUTI and uncomplicated urinary tract infections [6] Financial Impact - The transaction is expected to incur approximately CHF 15 million in additional research and development expenses in 2025, including the upfront payment and potential pre-commercial milestone payments [4]

The deposit portfolio grew by 71 million euros in July. This growth was led by the savings deposit product, which increased by 73 million euros, while the term deposit portfolio declined by 3 million euros. The trend continues where maturing term deposits are being redirected into the more flexible savings deposit product. The balance of Estonian retail customers' bank accounts grew by 1.0 million euros during the month, reaching 4.3 million euros by the end of July. All bank account holders continue to ear ...

About Kaldvík AS Kaldvík AS is the leading salmon farmer in Iceland. Kaldvik AS has a well-developed and fully integrated value-chain controlling all steps from hatchery to sales, enabling the group to provide its customers with a sustainable premium product. Kaldvik AS is dual-listed on Euronext Growth Oslo and First North Iceland Growth Market. See https://www.kaldvik.is for more information about the Company. Frøya, 14 August 2025: The board of directors (the "Board") of Kaldvík AS (the "Company") and Ro ...

Ad-hoc announcement pursuant to Article 53 of the SIX listing rules Kuros Biosciences Reports First Half of 2025 Results Financial Highlights Schlieren (Zurich), Switzerland, August 14, 2025 – Kuros Biosciences ("Kuros" or the "Company") a leader in next generation bone healing technologies, today announced its financial and operational results for the first half of 2025, demonstrating continued momentum in growth, broader market reach, and progress on key strategic priorities. Total group revenue reached U ...

Sanofi's rilzabrutinib earns orphan designation in the EU for IgG4-related disease Paris, August 14, 2025. The European Medicines Agency has granted orphan designation to rilzabrutinib, a reversible covalent Bruton's tyrosine kinase (BTK) inhibitor, for IgG4-related disease (IgG4-RD). EMA grants orphan designation to investigational therapies addressing rare, life-threatening or debilitating medical diseases or conditions that affect no more than 5 in 10,000 persons in the EU. Rilzabrutinib for the treatmen ...